Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients.
Réda ChebaniFlorian LombartGuillaume ChabyAli DadbanSébastien DebarbieuxManuelle-Anne ViguierSaskia Ingen Housz OroAnne Pham-LedardChristophe R BedaneCatherine Picard-DahanClémence BerthinOlivier DereureMaria-Polina KonstantinouMarion CastelFabienne JouenPascal JolyVannina SetaSophie Duvert-LehembreChristelle Le RouxGaëlle QuereuxBruno SassolasEmilie BrenautCarole SinMarie-Aleth RichardFrédéric BérardDelphine GiustiThibaut BelmondoThomas GilleFrédéric CauxCatherine Prost-SquarcioniSabine Mignot-GrootenboerMarina Alexandrenull nullPublished in: The British journal of dermatology (2023)
We report the largest series to date of BPs treated by omalizumab and confirm its effectiveness and safety in this indication. Serum baseline level of anti-BP180-NC16A IgE may predict response to treatment.